Our robust technology platform along with deep customer partnership has been the foundation of our success,” said Agena CEO Peter Dansky. “We are proud of our track record in bringing the power of genomics to the clinical setting in hereditary diseases, pharmacogenomics, oncology, infectious disease and sample integrity testing.
The announcement sent Mesa’s stock price climbing steadily upwards of $290 on Tuesday morning-up from $280 at Monday’s close-a point not seen since the end of January, save for a short-lived peak in late July. The transaction will be funded by a combination of Mesa’s cash on hand and a credit facility and is expected to be completed by the end of this year.
Mesa and Agena have reached a definitive agreement that will see Mesa offer up $300 million in cash to acquire the genetic test maker. Mesa is well on its way to joining the ranks of the medtech developers it currently counts as clients, thanks to its late 2019 acquisition of immunoassay tech maker Gyros Protein Technologies and, now, its proposed purchase of molecular diagnostics company Agena Bioscience.Īgena has developed the FDA-cleared MassArray genomic analysis platform, as well as a variety of assays to profile tumors, assess drug reactions, identify hereditary risks and detect biomarkers linked to a range of conditions, including non-small cell lung cancer, colorectal cancer, melanoma and COVID-19.
#Agena bioscience stock software
Though Mesa Laboratories has spent much of its lifetime working behind the scenes, manufacturing software and supplies used to help healthcare providers, medical device makers and life sciences labs run smoothly, the Colorado-based company is ready for its moment in the spotlight.
0 kommentar(er)
